CURATODERM

This brand name is authorized in Austria, Poland, United Kingdom

Active ingredients

The drug CURATODERM contains one active pharmaceutical ingredient (API):

1 Tacalcitol UNII B3Q63NVN9R - TACALCITOL MONOHYDRATE

Tacalcitol is a vitamin D3 derivative, which inhibits keratinocyte hyper-proliferation and induces differentiation of these cells. The normalisation of these mechanisms is the basis for the efficacy in the treatment of psoriasis. Read about Tacalcitol

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
CURATODERM Ointment	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
D05AX04	Tacalcitol	D Dermatologicals → D05 Antipsoriatics → D05A Antipsoriatics for topical use → D05AX Other antipsoriatics for topical use
Discover more medicines within D05AX04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 127734, 24541, 24544
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100077318